Cardiac saphenous vein bypass graft disease

Seminars in Vascular Medicine

Volumn 4, Issue 2, 2004, Pages 153-159

  Lau, G T ^a,b   Lowe, H C ^a,b,c   Kritharides, L ^a,b,c  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Coronary artery bypass grafting; Hyperlipidaemia; Intimal hyperplasia; Saphenous vein grafts

Indexed keywords

NITRIC OXIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; DEGENERATIVE DISEASE; DIABETES MELLITUS; ENDOTHELIUM INJURY; HEART SAPHENOUS VEIN BYPASS GRAFT DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPLASIA; HYPERTRIGLYCERIDEMIA; REVIEW; RISK FACTOR; SAPHENOUS VEIN GRAFT; STATISTICAL SIGNIFICANCE; THROMBOSIS;

CELL PROLIFERATION; CORONARY ARTERY BYPASS; DIABETIC ANGIOPATHIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERLIPIDEMIAS; NITRIC OXIDE; RISK FACTORS; SAPHENOUS VEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 7244245544     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835373     Document Type: Review

References (82)

1. Favaloro RG. Critical analysis of coronary artery bypass graft surgery: a 30-year journey. J Am Coll Cardiol 1998;31(4 suppl B):1B-63B
2. Possati G, Gaudino M, Prati F, et al. Long-term results of the radial artery used for myocardial revascularization. Circulation 2003;108(11):1350-1354
3. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225
4. RITA Trial Group. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993;341(8845):573-580
5. Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991;84(5 suppl):III275-III284
6. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998;97(9):916-931
7. Safian RD. Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis 2002;44(6):437-448
8. Landymore RW, MacAulay MA, Fris J. Effect of aspirin on intimal proliferation and tissue cholesterol in long-term experimental bypass grafts. Eur J Cardiothorac Surg 1992;6(8):422-426
9. Batayias GE, Barboriak JJ, Korns ME, Pintar K. The spectrum of pathologic changes in aortocoronary saphenous vein grafts. Circulation 1977;S6(3 Suppl):II18-II22
10. Moor E, Hamsten A, Blomback M, Herzfeld I, Wiman B, Ryden L. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost 1994;72(3):335-342
11. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82(11):3350- 3357
12. Golledge J, Gosling M, Turner RJ, Standfield NJ, Powell JT. Arterial flow induces changes in saphenous vein endothelium proteins transduced by cation channels. Eur J Vasc Endovasc Surg 2000;19(5):545-550
13. Golledge J, Turner RJ, Gosling M, Powell JT. Rapid changes in the coagulant proteins on saphenous vein endothelium in response to arterial flow. Angiology 1999;50(9):693-701
14. Tsui JC, Souza DS, Filbey D, Bomfim V, Dashwood MR. Preserved endothelial integrity and nitric oxide synthase in saphenous vein grafts harvested by a 'no-touch' technique. Br J Surg 2001;88(9):1209-1215
15. Marx N, Neumann FJ, Zohlnhofer D, et al. Enhancement of monocyte procoagulant activity by adhesion on vascular smooth muscle cells and intercellular adhesion molecule-1-transfected Chinese hamster ovary cells. Circulation 1998;98(9):906-911
16. Yamada T, Itoh T, Nakano S, Tokunaga O. Time-dependent thickening of the intima in aortocoronary saphenous vein grafts: clinicopathological analysis of 24 patients. Heart Vessels 1995;10(1):41-45
17. Hozumi T, Yoshikawa J, Yoshida K, et al. Use of intravascular ultrasound for in vivo assessment of changes in intimal thickness of angiographically normal saphenous vein grafts one year after aortocoronary bypass surgery. Heart 1996;76(4):317-320
18. Willard JE, Netto D, Demian SE, et al. Intravascular ultrasound imaging of saphenous vein grafts in vitro: comparison with histologic and quantitative angiographic findings. J Am Coll Cardiol 1992;19(4):759-764
19. Marin ML, Veith FJ, Panetta TF, et al. Saphenous vein biopsy: a predictor of vein graft failure. J Vasc Surg 1993;18(3):407-414
20. Campbell GR, Campbell JH. The phenotypes of smooth muscle expressed in human atheroma. Ann N Y Acad Sci 1990;598:143-158
21. Amano J, Suzuki A, Sunamori M, Tsukada T, Numano F. Cytokinetic study of aortocoronary bypass vein grafts in place for less than six months. Am J Cardiol 1991;67(15):1234-1236
22. Mehta D, George SJ, Jeremy JY, et al. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med 1998;4(2):235-239
23. Tanner FC, Boehm M, Akyurek LM, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kipl), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000;101(17):2022-2025
24. Crook MF, Akyurek LM. Gene transfer strategies to inhibit neointima formation. Trends Cardiovasc Med 2003;13(3):102-106
25. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000;101(16):1982-1989
26. Salvemini D, Radziszewski W, Korbut R, Vane J. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 1990;101(4):991-995
27. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg 1995;60(3):773-777
28. Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991;5(7):2029-2034
29. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78(2):225-230
30. Best PJ, Hasdai D, Sangiorgi G, et al. Apoptosis. Basic concepts and implications in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19(1):14-22
31. Guo JP, Murohara T, Buerke M, Scalia R, Lefer AM. Direct measurement of nitric oxide release from vascular endothelial cells. J Appl Physiol 1996;81(2):774-779
32. Dignan RJ, Dyke CM, Abd-Elfattah AS, et al. Coronary artery endothelial cell and smooth muscle dysfunction after global myocardial ischemia. Ann Thorac Surg 1992;53(2):311-317
33. Nakanishi K, Zhao ZQ, Vinten-Johansen J, Lewis JC, McGee DS, Hammon JW Jr. Coronary artery endothelial dysfunction after global ischemia, blood cardioplegia, and reperfusion. Ann Thorac Surg 1994;58(1):191-199
34. Kown MH, Yamaguchi A, Jahncke CL, et al. L-arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 2001;121(5):971-980
35. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91(11):2793-2801
36. Grotendorst GR, Soma Y, Takehara K, Charette M. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989;139(3):617-623
37. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci 2001;947:42-54
38. Lindner V, Reidy MA. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol 1995;146(6):1488- 1497
39. Banai S, Wolf Y, Colomb G, et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998;97:1960-1969
40. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68(1):106-113
41. Lowe HC, Chesterman CN, Hopkins AP, Juergens CP, Khachigian LM. Acute local release of fibroblast growth factor-2 but not transforming growth factor-betal following coronary stenting. Thromb Haemost 2001;85(3):574-576
42. Lindner V. Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. Z Kardiol 1995;(84 Suppl 4):137-144
43. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ Res 1993;73(3):589-595
44. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88(9):3739-3743
45. Neschis DG, Safford SD, Hanna AK, Fox JC, Golden MA. Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J Vasc Surg 1998;27(1):126-134
46. Khachigian LM, Collins T. Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ Res 1997;81(4):457-461
47. Santiago FS, Lowe HC, Kavurma MM, et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999;5(12):1438
48. Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res 2001;89(8):670-677
49. Bjorkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb 1991;11(4):892-902
50. Atkinson JB, Forman MB, Vaughn WK, Robinowitz M, McAllister HA, Virmani R. Morphologic changes in long-term saphenous vein bypass grafts. Chest 1985;88(3):341-348
51. Newby AC. Molecular and cell biology of native coronary and vein-graft atherosclerosis: regulation of plaque stability and vessel-wall remodelling by growth factors and cell-extracellular matrix interactions. Coron Artery Dis 1997;8(3-4):213-224
52. Hong MK, Mintz GS, Hong MK, et al. Intravascular ultrasound assessment of the presence of vascular remodeling in diseased human saphenous vein bypass grafts. Am J Cardiol 1999;84(9):992-998
53. Shuhaiber JH, Evans AN, Massad MG, Geha AS. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg 2002;22(3):387-396
54. Porter KE, Loftus IM, Peterson M, Bell PR, London NJ, Thompson MM. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br J Surg 1998;85(10):1373-1377
55. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60(4):577-584
56. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804
57. Kukielka GL, Hawkins HK, Michael L, et al. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. J Clin Invest 1993;92(3):1504-1516
58. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988;78(3 Pt 2):I140-I143
59. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311(21):1329-1332
60. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986;6(6):594-600
61. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-3017
62. Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999;99(25):3241-3247
63. Linden T, Bondjers G, Karlsson T, Wiklund O. Serum triglycerides and HDL cholesterol-major predictors of long-term survival after coronary surgery. Eur Heart J 1994;15(6):747-752
64. Cataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E. Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA). Circulation 1993;88(5 Pt 2):II93-I198
65. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992;152(1): 28-34
66. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100(10):1134-1146
67. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003;92(4A):18J-26J
68. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002;118(1):255-259
69. Puccetti L, Bruni F, Pasqui AL, et al. Dyslipidemias and fibrinolysis. Ital Heart J 2002;3(10):579-586
70. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001;86(1):386-394
71. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999;103(2):219-227
72. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002;25(6):989-994
73. Mompeo B, Ortega F. Immunohistochemical and ultrastrucrural study of microvessels in diabetic veins. Ultrastruct Pathol 1999;23(1):25-31
74. Wengerter KR, Veith FJ, Gupta SK, Ascer E, Rivers SP. Influence of vein size (diameter) on infrapopliteal reversed vein graft patency. J Vasc Surg 1990;11(4):525-531
75. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999;84:459-461
76. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. J Am Coll Cardiol 1995;26(4):895-899
77. Eritsland J, Arnesen H, Seljeflot I, et al. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol 1994;74(11):1099-1102
78. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354(9189):1493-1498
79. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001;121(4):714-722
80. Shigematsu K, Yasuhara H, Shigematsu H. Topical application of antiangiogenic agent AGM-1470 suppresses anastomotic intimal hyperplasia after ePTFE grafting in a rabbit model. Surgery 2001;129(2):220-230
81. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349(24):2316-2325
82. Dzau VJ. Predicting the future of human gene therapy for cardiovascular diseases: what will the management of coronary artery disease be like in 2005 and 2010? Am J Cardiol 2003; 92(9B):32N-35N